When. Trials. Matter.

Our Therapeutic Areas

CNS diseases.  
Cardio-Metabolic and Renal diseases.  
Infectious diseases.

Central Nervous System

CNS disease prevalence is rising, and available treatments for many are either minimally effective or nonexistent. CNS is one of the primary therapeutic areas where we have chosen to focus efforts. 

Read more

Cardio-Metabolic and Renal

Julius Clinical’s focused approach has created a track record of excellence that testifies to our cardio-metabolic and kidney disease trial capabilities. We have honed our scientific site networks, collaborations with leading experts, and operational resources to deliver steady streams of patients and high-quality data for clients. 

Read more

Infectious Diseases & Vaccines

Unrecognised pathogens and reemerging infectious diseases are an ongoing threat to human health in every corner of the world. We contribute to important research in this area by conducting pioneering infectious disease and vaccine trials, doing what we do best: optimizing protocols and executing streamlined trials that deliver high-quality data.

Read more

Central Nervous System

CNS disease prevalence is rising, and available treatments for many are either minimally effective or nonexistent. CNS is one of the primary therapeutic areas where we have chosen to focus efforts. 

Read more

Cardio-Metabolic and Renal

Julius Clinical’s focused approach has created a track record of excellence that testifies to our cardio-metabolic and kidney disease trial capabilities. We have honed our scientific site networks, collaborations with leading experts, and operational resources to deliver steady streams of patients and high-quality data for clients. 

Read more

Infectious Diseases & Vaccines

Unrecognised pathogens and reemerging infectious diseases are an ongoing threat to human health in every corner of the world. We contribute to important research in this area by conducting pioneering infectious disease and vaccine trials, doing what we do best: optimizing protocols and executing streamlined trials that deliver high-quality data.

Read more

A selection of our trials

Discover our story

Our Unique Triangle

Our industry-leading combination of scientific leadership, site networks, and operational excellence forms the unique triangle that is the foundation of our success.

  • News
  • Cardio-Metabolic and Renal Diseases, MASH (NASH)

Metabolic dysfunction associated steatotic liver disease and the heart

Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius ClinicalThe estimated prevalence of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in the adult population is 31% ...

By: Michelle Heuvelmans
  • Cardio-Metabolic and Renal Diseases

Upcoming webinar – Getting GRIP on MASH after LITMUS

On March 12th, we will organise the webinar: Getting GRIP on MASH after LITMUSDuring this webinar, our speaker and hosts will dive into the following topics:The usefulness of noninvasive diagnostic methods depends on the prevalence of t...

Download

"*" indicates required fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Request for proposal

"*" indicates required fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
This field is for validation purposes and should be left unchanged.

Share

Twitter Facebook LinkedIn